Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Qiu, Miaozhen ^a,b   Zhou, Yixin ^a   Zhang, Xinke ^a   Wang, Zixian ^c   Wang, Fang ^a   Shao, Jianyong ^a   Lu, Jiabin ^a   Jin, Ying ^a   Wei, Xiaoli ^a   Zhang, Dongsheng ^a   Wang, Fenghua ^a   Li, Yuhong ^a   Yang, Dajun ^a   Xu, Ruihua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gastric cancer; Human epidermal growth factor receptor 2; Lauren classification; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; LAUREN CLASSIFICATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSTIC ASSESSMENT; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; ADOLESCENT; CANCER GRADING; CHEMISTRY; CHINA; CLASSIFICATION; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; STOMACH TUMOR; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84964315680     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-823     Document Type: Article

References (24)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
2. Moore MA, Eser S, Igisinov N, Igisinov S, Mohagheghi MA, Mousavi-Jarrahi A, Ozenturk G, Soipova M, Tuncer M, Sobue T: Cancer epidemiology and control in North-Western and Central Asia-past, present and future. Asian Pac J Cancer Prev 2010, 11(Suppl 2):17-32.
3. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, Hwang TL, Jan YY, Yeh TS: Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 2011, 16(12):1706-1713.
4. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, Liu JP, Bu H, Zhou XY, Du X: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013, 24(9):2360-2364.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
6. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkins H, Hahnel R: The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 1994, 56(1):61-65.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
8. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992, 10(7):1044-1048.
9. Gomez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodriguez-Peralto JL, Hidalgo M, Lopez-Rios F: HER2/neu testing for anti- HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 2012, 65(8):751-757.
10. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW: c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991, 48(5):668-671.
11. Jorgensen JT, Hersom M: HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer 2012, 3:137-144.
12. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q: Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013, 19(14):2171-2178.
13. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012, 23(10):2656-2662.
14. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y: HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013, 16(1):84-93.
15. Qiu MZ, Li Q, Wang ZQ, Liu TS, Liu Q, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Zhang DS, Wang FH, Li YH, Xu RH: HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer 2014, 134(10):2468-2477.
16. Liang JW, Zhang JJ, Zhang T, Zheng ZC: Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour Biol 2014, 35(5):4849-4858.
17. Lauren P: THE two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965, 64:31-49.
18. Qiu MZ, Cai MY, Zhang DS, Wang ZQ, Wang DS, Li YH, Xu RH: Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med 2013, 11:58.
19. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16(2):273-278.
20. Yamashita K, Sakuramoto S, Katada N, Futawatari N, Moriya H, Hirai K, Kikuchi S, Watanabe M: Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer. Hepato-Gastroenterology 2009, 56(89):276-281.
21. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007, 60(3):273-277.
22. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375(9712):377-384.
23. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA: Evaluating the yield of medical tests. JAMA 1982, 247(18):2543-2546.
24. Kurokawa Y, Matsuura N, Kimura Y, Kawabata R, Adachi S, Fujita J, Nishikawa K, Takiguchi S, Mori M, Doki Osaka/JP Y: Survival impact of HER2 status in patients with gastric cancer: a multicenter large-scale study in Japan. ESMO Abstr 2012, 677P. http://abstracts.webges.com/myitinerary/session-296.html? congress=esmo2012.